• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharmaceutical Executive's 2022 Emerging Pharma Leaders

Pharmaceutical ExecutivePharmaceutical Executive-05-01-2022
Volume 42
Issue 5

Pharm Exec profiles its 2022 Emerging Pharma Leaders.

Click on the links below to read the profiles of Pharm Exec's 2022 Emerging Pharma Leaders.

Naveen Bazaj, Head of Corporate Development, Alector

Gardner Gendron, Chief/US Head of Commercial, NS Pharma

Aida Habtezion, MD, Senior VP, Chief Medical Officer, and Head of Worldwide Medical and Safety, Pfizer

Matthew J. Hawryluk, PhD, Executive VP, Chief Business Officer and Cambridge Site Head, Gritstone bio

Charmaine Lykins, Chief Commercial Officer, Karuna Therapeutics

Divya Chadha Manek, Senior Vice President of Clinical Development, Eyebiotech Limited (EyeBio)

Susan Pandya, MD, Vice President, Clinical Development, and Head of Cancer Metabolism Global Development Oncology and Immuno-Oncology, Servier Pharmaceuticals

Matthew R. Price, Co-Founder, Executive Vice President, Chief Operating Officer, and Board Director, Promontory Therapeutics

Quiona Russell, PhD, Associate Director of Medical Information and Medical Communication, G1 Therapeutics

Patricia Torr, US President and General Manager, Idorsia Pharmaceuticals

Shetal Vyas, Vice President of Operations, Ferring Pharmaceuticals

*From a pool of nominations, these final selections were judged in a blinded process by three Pharmaceutical Executive Editorial Advisory Board members and a former EPL. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with executives most likely to inhabit key “c-suite” functions.

Related Videos